| 2023 | Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer | BRITISH JOURNAL OF CANCER |
| 2023 | Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2023 | CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy | CLINICAL CANCER RESEARCH |
| 2023 | Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer
| FRONTIERS IN ONCOLOGY |
| 2022 | PREDICTION OF SURGICAL OUTCOMES OF INTERVAL DEBULKING SURGERY (IDS) USING IN ADVANCED OVARIAN CANCER: A NOVEL SCORING SYSTEM USING POST-NEOADJUVANT CHEMOTHERAPY (NAC) COMPUTED TOMOGRAPHY (CT) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | OREGOVOMAB AND NON-PLATINUM SINGLE AGENT CHEMOTHERAPY IN PARP INHIBITOR-RESISTANT OVARIAN CANCER PATIENTS NOT CANDIDATE FOR PLATINUM RETREATMENT: A MULTI-COHORT PHASE II STUDY (KGOG 3065/APGOT-OV6) | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | IMMUNE PROPERTIES OF TUMOR-INFILTRATING LYMPHOCYTES IN OVARIAN CLEAR CELL CARCINOMA RELATIVE TO OVARIAN HIGH-GRADE SEROUS CARCINOMA | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2) RECEPTOR EXPRESSION AND ITS DYNAMIC CHANGE IN OVARIAN CANCER PATIENTS | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | Dynamic changes of peripheral regulatory t cells during parp inhibitor maintenance therapy in patients with ovarian cancer | INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER |
| 2022 | Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study | GYNECOLOGIC ONCOLOGY |
| 2022 | Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study | GYNECOLOGIC ONCOLOGY |
| 2022 | A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2021 | Comparison of the Prognostic Outcome between High-Grade Ovarian Sertoli-Leydig Cell Tumors (SLCTs) and Low-Grade SLCTs
| YONSEI MEDICAL JOURNAL |
| 2020 | 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 + CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
| YONSEI MEDICAL JOURNAL |
| 2019 | How to use immune checkpoint inhibitor in ovarian cancer?
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
http://orcid.org/0000-0003-4094-2097
